Novel small molecule Raf kinase inhibitors for targeted cancer therapeutics
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Novel small molecule Raf kinase inhibitors for targeted cancer therapeutics
Authors
Keywords
-
Journal
ARCHIVES OF PHARMACAL RESEARCH
Volume 35, Issue 4, Pages 605-615
Publisher
Springer Nature
Online
2012-05-02
DOI
10.1007/s12272-012-0403-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Human cerebrovascular contractile receptors are upregulated via a B-Raf/MEK/ERK-sensitive signaling pathway
- (2011) Hilda Ahnstedt et al. BMC NEUROSCIENCE
- Multitargeted receptor tyrosine kinase inhibition: An antiangiogenic strategy in non-small cell lung cancer
- (2011) Mark A. Socinski CANCER TREATMENT REVIEWS
- The novel Raf inhibitor Raf265 decreases Bcl-2 levels and confers TRAIL-sensitivity to neuroendocrine tumour cells
- (2011) K. Zitzmann et al. ENDOCRINE-RELATED CANCER
- Overview of anti-angiogenic agents in development for ovarian cancer
- (2011) Robert A. Burger GYNECOLOGIC ONCOLOGY
- The BRAFT1799A mutation confers sensitivity of thyroid cancer cells to the BRAFV600E inhibitor PLX4032 (RG7204)
- (2010) Joanna Xing et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- BRAF as therapeutic target in melanoma
- (2010) Claudia Wellbrock et al. BIOCHEMICAL PHARMACOLOGY
- Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
- (2010) Jessie Villanueva et al. CANCER CELL
- RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models
- (2010) H. Yang et al. CANCER RESEARCH
- Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
- (2010) Sonja J. Heidorn et al. CELL
- MEK-Independent Survival of B-RAFV600E Melanoma Cells Selected for Resistance to Apoptosis Induced by the RAF Inhibitor PLX4720
- (2010) C. C. Jiang et al. CLINICAL CANCER RESEARCH
- Clinical overview of sorafenib in breast cancer
- (2010) Alvaro Moreno-Aspitia Future Oncology
- Dependence on Phosphoinositide 3-Kinase and RAS-RAF Pathways Drive the Activity of RAF265, a Novel RAF/VEGFR2 Inhibitor, and RAD001 (Everolimus) in Combination
- (2010) P. Mordant et al. MOLECULAR CANCER THERAPEUTICS
- Sorafenib Inhibits STAT3 Activation to Enhance TRAIL-Mediated Apoptosis in Human Pancreatic Cancer Cells
- (2010) S. Huang et al. MOLECULAR CANCER THERAPEUTICS
- Drug discovery: Inhibitors that activate
- (2010) Karen Cichowski et al. NATURE
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
- (2010) Poulikos I. Poulikakos et al. NATURE
- RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
- (2010) Georgia Hatzivassiliou et al. NATURE
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
- (2010) Gideon Bollag et al. NATURE
- COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
- (2010) Cory M. Johannessen et al. NATURE
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
- (2010) Ramin Nazarian et al. NATURE
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- (2010) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hyperactivation of MEK–ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells
- (2010) F M Kaplan et al. ONCOGENE
- PLX4032, a selective BRAFV600E kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAFWT melanoma cells
- (2010) Ruth Halaban et al. Pigment Cell & Melanoma Research
- A Phase II Trial of Sorafenib in Metastatic Melanoma with Tissue Correlates
- (2010) Patrick A. Ott et al. PLoS One
- The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner
- (2010) E. W. Joseph et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- BRAF Gene Amplification Can Promote Acquired Resistance to MEK Inhibitors in Cancer Cells Harboring the BRAF V600E Mutation
- (2010) R. B. Corcoran et al. Science Signaling
- Targeting the RAF–MEK–ERK pathway in cancer therapy
- (2009) Clara Montagut et al. CANCER LETTERS
- Sorafenib Inhibits Non-Small Cell Lung Cancer Cell Growth by Targeting B-RAF in KRAS Wild-Type Cells and C-RAF in KRAS Mutant Cells
- (2009) K. Takezawa et al. CANCER RESEARCH
- Antitumor Efficacy of the Novel RAF Inhibitor GDC-0879 Is Predicted by BRAFV600E Mutational Status and Sustained Extracellular Signal-Regulated Kinase/Mitogen-Activated Protein Kinase Pathway Suppression
- (2009) K. P. Hoeflich et al. CANCER RESEARCH
- BRAF Signaling and Targeted Therapies in Melanoma
- (2009) Nathalie Dhomen et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines
- (2009) Paola Ulivi et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma
- (2009) Axel Hauschild et al. JOURNAL OF CLINICAL ONCOLOGY
- Sorafenib induces growth suppression in mouse models of gastrointestinal stromal tumor
- (2009) H. Huynh et al. MOLECULAR CANCER THERAPEUTICS
- Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma
- (2008) C. Montagut et al. CANCER RESEARCH
- Mutant FLT3: A Direct Target of Sorafenib in Acute Myelogenous Leukemia
- (2008) Weiguo Zhang et al. JNCI-Journal of the National Cancer Institute
- BRAF Silencing by Short Hairpin RNA or Chemical Blockade by PLX4032 Leads to Different Responses in Melanoma and Thyroid Carcinoma Cells
- (2008) E. Sala et al. MOLECULAR CANCER RESEARCH
- Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas
- (2008) F. Yang et al. MOLECULAR CANCER THERAPEUTICS
- Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
- (2008) J. Tsai et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now